EA017668B1 - Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов - Google Patents

Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов Download PDF

Info

Publication number
EA017668B1
EA017668B1 EA201070762A EA201070762A EA017668B1 EA 017668 B1 EA017668 B1 EA 017668B1 EA 201070762 A EA201070762 A EA 201070762A EA 201070762 A EA201070762 A EA 201070762A EA 017668 B1 EA017668 B1 EA 017668B1
Authority
EA
Eurasian Patent Office
Prior art keywords
compound
mol
formula
hours
dibenzo
Prior art date
Application number
EA201070762A
Other languages
English (en)
Russian (ru)
Other versions
EA201070762A1 (ru
Inventor
Константинос Гавардинас
Прабхакар Кондаджи Джадхав
Original Assignee
Эли Лилли Энд Компани
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40430143&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EA017668(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Эли Лилли Энд Компани filed Critical Эли Лилли Энд Компани
Publication of EA201070762A1 publication Critical patent/EA201070762A1/ru
Publication of EA017668B1 publication Critical patent/EA017668B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/40—Mineralocorticosteroids, e.g. aldosterone; Drugs increasing or potentiating the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EA201070762A 2007-12-19 2008-12-09 Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов EA017668B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1477607P 2007-12-19 2007-12-19
PCT/US2008/085997 WO2009085584A1 (en) 2007-12-19 2008-12-09 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists

Publications (2)

Publication Number Publication Date
EA201070762A1 EA201070762A1 (ru) 2010-12-30
EA017668B1 true EA017668B1 (ru) 2013-02-28

Family

ID=40430143

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070762A EA017668B1 (ru) 2007-12-19 2008-12-09 Производные 6н-дибензо[b,e]оксепина в качестве нестероидных антагонистов минералокортикоидных рецепторов

Country Status (33)

Country Link
US (1) US7994164B2 (enExample)
EP (2) EP2537845B1 (enExample)
JP (1) JP5562866B2 (enExample)
KR (1) KR101254382B1 (enExample)
CN (1) CN101903377B (enExample)
AR (1) AR069554A1 (enExample)
AU (1) AU2008343524B2 (enExample)
BR (1) BRPI0820805A2 (enExample)
CA (1) CA2710409C (enExample)
CL (1) CL2008003600A1 (enExample)
CO (1) CO6300953A2 (enExample)
DK (1) DK2235007T3 (enExample)
DO (1) DOP2010000185A (enExample)
EA (1) EA017668B1 (enExample)
EC (2) ECSP10010266A (enExample)
ES (2) ES2396605T3 (enExample)
GT (1) GT201000179A (enExample)
HR (1) HRP20120916T1 (enExample)
IL (1) IL206353A (enExample)
MA (1) MA31910B1 (enExample)
MX (1) MX2010006911A (enExample)
MY (1) MY150474A (enExample)
NZ (1) NZ586300A (enExample)
PE (1) PE20091057A1 (enExample)
PL (1) PL2235007T3 (enExample)
PT (1) PT2235007E (enExample)
RS (1) RS52594B (enExample)
SI (1) SI2235007T1 (enExample)
TN (1) TN2010000292A1 (enExample)
TW (1) TWI431010B (enExample)
UA (1) UA100131C2 (enExample)
WO (1) WO2009085584A1 (enExample)
ZA (1) ZA201004257B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009018657A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
EP2234977A4 (en) 2007-12-19 2011-04-13 Boehringer Ingelheim Int VIRAL POLYMERASE INHIBITORS
WO2010104721A1 (en) * 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use
EP2568986B1 (en) 2010-05-10 2016-01-13 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and compositions for the treatment of fluid accumulation in and/ or under the retina
EP2582365B1 (en) 2010-06-16 2019-03-20 INSERM (Institut National de la Santé et de la Recherche Médicale) Compositions for stimulating reepithelialisation during wound healing
CN102060670A (zh) * 2011-01-04 2011-05-18 常州大学 一种2-溴-6-氟苯甲醇的制备方法
MD20150103A2 (ro) 2013-05-02 2016-02-29 Pfizer Inc. Derivaţi ai imidazo-triazinei ca inhibitori ai PDE10
AR099416A1 (es) 2014-02-28 2016-07-20 Lilly Co Eli Terapia combinada para la hipertensión resistente
ME03316B (me) 2014-06-30 2019-10-20 Astrazeneca Ab Benzoksazinon amidi као modulatori mineralokorтikoidnog receptora
JP2017531684A (ja) * 2014-11-21 2017-10-26 イーライ リリー アンド カンパニー 腎障害の治療のための１，２−ベンゾチアゾール化合物
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
EP3490606B8 (en) 2016-07-26 2024-04-10 INSERM (Institut National de la Santé et de la Recherche Médicale) Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
WO2018054357A1 (zh) * 2016-09-24 2018-03-29 山东亨利医药科技有限责任公司 含盐皮质激素受体拮抗剂的药物组合物及其用途
EP4118235B1 (en) 2020-03-11 2026-08-05 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea
CN117510398A (zh) * 2023-11-02 2024-02-06 上海诺丁太生物科技有限公司 一种高光学纯度(3r,4r)/(3s,4s)-n-boc-4-氨基-3-羟基哌啶的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345747A2 (en) * 1988-06-09 1989-12-13 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4072756A (en) * 1973-05-17 1978-02-07 Sandoz Ltd. Tricyclo piperidino ketones and soporific compositions thereof
SE426341C (sv) * 1980-02-14 1985-09-23 Fagersta Ab Sett att forhindra korrosion i en forbrenningsanleggnings kylare och skorsten vid kylning av rokgaser
FR2603713B1 (fr) * 1986-09-10 1992-07-24 Canon Kk Derive nouveau de 5h-dibenzo(a,d)cycloheptane-(ene)ylidene, son procede de production et support electrophotographique photosensible le contenant
GB8914061D0 (en) * 1989-06-19 1989-08-09 Wellcome Found Agents for potentiating the effects of antitumour agents and combating multiple drug resistance
US5378701A (en) * 1991-12-27 1995-01-03 Kyowa Hakko Kogyo Tricyclic compounds
US6372779B1 (en) 1997-12-29 2002-04-16 Ortho Pharmaceutical Corporation Anti-inflammatory compounds
EP1154997A4 (en) 1999-01-26 2002-11-04 Dana Farber Cancer Inst Inc PHARMACEUTICALLY ACTIVE COMPOUNDS AND METHODS OF USE
ES2260497T7 (es) * 2001-11-21 2009-11-05 Millennium Pharmaceuticals, Inc. Antagonistas de receptores de quimioquininas y metodos de uso de los mismos.
WO2005066153A1 (en) 2003-12-19 2005-07-21 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators
DE602004014640D1 (de) * 2003-12-19 2008-08-07 Lilly Co Eli Tricyclische modulatoren von nuklearen steroidhormonrezeptoren
TWI350168B (en) 2004-05-07 2011-10-11 Incyte Corp Amido compounds and their use as pharmaceuticals
RU2007107177A (ru) * 2004-07-28 2008-09-10 Айрм Ллк (Bm) Соединения и композиции, как модуляторы ядерных рецепторов стероидных гормонов
SG161261A1 (en) 2004-11-10 2010-05-27 Incyte Corp Lactam compounds and their use as pharmaceuticals
ES2375877T3 (es) 2006-10-31 2012-03-07 Pfizer Products Inc. Compuestos de pirazolina como antagonistas de receptores de mineralocorticoides.
JP2010522732A (ja) 2007-03-29 2010-07-08 ナームローゼ・フエンノートチヤツプ・オルガノン 鉱質コルチコイド受容体アンタゴニスト
PE20091339A1 (es) 2007-12-21 2009-09-26 Glaxo Group Ltd Derivados de oxadiazol con actividad sobre receptores s1p1
GB0725102D0 (en) 2007-12-21 2008-01-30 Glaxo Group Ltd Compounds
WO2009094157A1 (en) 2008-01-25 2009-07-30 Arena Pharmaceuticals, Inc. Dihydro- 1h- pyrrolo [1,2-a] indol-1-yl carboxylic derivatives which act as s1p1 agonists
WO2010104721A1 (en) 2009-03-12 2010-09-16 Eli Lilly And Company Mineralocorticoid receptor antagonist and methods of use

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0345747A2 (en) * 1988-06-09 1989-12-13 Kyowa Hakko Kogyo Co., Ltd. Tricyclic compounds
WO2004052847A2 (en) * 2002-06-26 2004-06-24 Eli Lilly And Company Tricyclic steroid hormone nuclear receptor modulators

Also Published As

Publication number Publication date
MA31910B1 (fr) 2010-12-01
PT2235007E (pt) 2013-01-22
HRP20120916T1 (hr) 2012-12-31
AR069554A1 (es) 2010-02-03
EP2537845A1 (en) 2012-12-26
EA201070762A1 (ru) 2010-12-30
ES2459318T3 (es) 2014-05-09
UA100131C2 (uk) 2012-11-26
MY150474A (en) 2014-01-30
AU2008343524B2 (en) 2012-03-08
DOP2010000185A (es) 2010-09-15
PE20091057A1 (es) 2009-07-20
ZA201004257B (en) 2011-11-30
PL2235007T3 (pl) 2013-03-29
TN2010000292A1 (en) 2011-11-11
CN101903377A (zh) 2010-12-01
NZ586300A (en) 2012-06-29
CN101903377B (zh) 2014-07-09
JP2011507868A (ja) 2011-03-10
EP2235007B1 (en) 2012-10-31
HK1144284A1 (en) 2011-02-11
CA2710409C (en) 2012-11-06
KR101254382B1 (ko) 2013-04-15
CO6300953A2 (es) 2011-07-21
TWI431010B (zh) 2014-03-21
BRPI0820805A2 (pt) 2015-06-16
ECSP12012048A (es) 2012-08-31
RS52594B (sr) 2013-04-30
ECSP10010266A (es) 2010-07-30
GT201000179A (es) 2012-04-16
CL2008003600A1 (es) 2010-02-19
KR20100082866A (ko) 2010-07-20
ES2396605T3 (es) 2013-02-22
SI2235007T1 (sl) 2013-01-31
EP2537845B1 (en) 2014-03-19
US7994164B2 (en) 2011-08-09
TW200930721A (en) 2009-07-16
WO2009085584A1 (en) 2009-07-09
IL206353A0 (en) 2010-12-30
CA2710409A1 (en) 2009-07-09
US20090163472A1 (en) 2009-06-25
EP2235007A1 (en) 2010-10-06
IL206353A (en) 2014-06-30
DK2235007T3 (da) 2012-12-17
MX2010006911A (es) 2010-10-05
AU2008343524A1 (en) 2009-07-09
JP5562866B2 (ja) 2014-07-30

Similar Documents

Publication Publication Date Title
JP5562866B2 (ja) 鉱質コルチコイド受容体アンタゴニストおよび使用方法
JP6908536B2 (ja) ムスカリンｍ２受容体の正のアロステリックモジュレーター
EP4647433A1 (en) Shp2 inhibitor and uses thereof
CA3104377C (en) Heterocyclic compounds as trk inhibitors
TW202400608A (zh) 雜芳族巨環醚化合物之固體形式、醫藥組合物及製備
EA029311B1 (ru) Hантагонисты, имеющие феноксипиперидиновое ядро в структуре, и их применение для лечения и/или профилактики состояний, опосредуемых hрецепторами
CN111479813A (zh) 作为加压素v1a受体拮抗剂的三唑并苯并吖庚因
CN109689656B (zh) 7-取代的1-芳基二氮杂萘-3-羧酰胺及其用途
TW202417458A (zh) 調節her2的化合物及方法
TW202204343A (zh) 經取代之３－苯氧基氮雜環丁烷－１－基－吡
US20250177539A1 (en) Er degraders and uses thereof
KR20080070822A (ko) 유도가능 산화질소 신타제 이량체화 억제제의 염
HK1144284B (en) 6h-dibenz0 [b, e] oxepine derived nonsteroidal mineralocorticoid receptor antagonists
WO2025122809A1 (en) M4 positive allosteric modulators
WO2026039512A1 (en) Kras inhibitors
TW202430523A (zh) pan-KRAS降解劑及其製備方法與應用

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): BY KG MD TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ TJ RU